Applied Therapeutics Stock (NASDAQ:APLT)
Previous Close
$9.63
52W Range
$1.79 - $9.98
50D Avg
$7.62
200D Avg
$5.68
Market Cap
$1.11B
Avg Vol (3M)
$2.57M
Beta
2.04
Div Yield
-
APLT Company Profile
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
APLT Performance
Peer Comparison
Ticker | Company |
---|---|
PMVP | PMV Pharmaceuticals, Inc. |
XFOR | X4 Pharmaceuticals, Inc. |
CGEM | Cullinan Oncology, Inc. |
SEER | Seer, Inc. |
BCAB | BioAtla, Inc. |
MLYS | Mineralys Therapeutics, Inc. |
DAWN | Day One Biopharmaceuticals, Inc. |
HOOK | HOOKIPA Pharma Inc. |
ACRV | Acrivon Therapeutics, Inc. Common Stock |
GANX | Gain Therapeutics, Inc. |
TERN | Terns Pharmaceuticals, Inc. |
ORIC | ORIC Pharmaceuticals, Inc. |
LTRN | Lantern Pharma Inc. |
CCCC | C4 Therapeutics, Inc. |
TFFP | TFF Pharmaceuticals, Inc. |
INAB | IN8bio, Inc. |
VINC | Vincerx Pharma, Inc. |
ANEB | Anebulo Pharmaceuticals, Inc. |
MOLN | Molecular Partners AG |
LIFE | aTyr Pharma, Inc. |
LYRA | Lyra Therapeutics, Inc. |
STTK | Shattuck Labs, Inc. |